Event Free Survival Length of study [clinicaltrials_resource:67cd6fa546d5ae4e7a56564ca1e27580]
Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Event Free Survival Length of study [clinicaltrials_resource:67cd6fa546d5ae4e7a56564ca1e27580]
Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
Bio2RDF identifier
67cd6fa546d5ae4e7a56564ca1e27580
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:67cd6fa546d5ae4e7a56564ca1e27580
measure [clinicaltrials_vocabulary:measure]
Event Free Survival
time frame [clinicaltrials_vocabulary:time-frame]
Length of study
description
Patients are observed if their ...... ype of leukemia that develops.
identifier
clinicaltrials_resource:67cd6fa546d5ae4e7a56564ca1e27580
title
Event Free Survival Length of study
@en
type
label
Event Free Survival Length of ...... d6fa546d5ae4e7a56564ca1e27580]
@en